Suven Life announces Phase-3 narcolepsy study at SLEEP-2026

Suven Life announces Phase-3 narcolepsy study at SLEEP-2026 — Suven Life Sciences will present three posters on Samelisant (SUVN-G3031), including global Phase-3 data from the AWAKE study in narcolepsy, at the SLEEP-2026 Annual Meeting. The presentations highlight key clinical advancements for its lead candidate. This boosts visibility among global researchers and potential partners. Regulatory approval could open a $1.2B market opportunity in sleep disorders.

📊 STOCKS: SUVENLIFE | 🏢 SECTOR: Pharma | #MEDIUMIMPACT #ClinicalTrial